Silexion Therapeutics Files 10-Q Post Reverse Split

Ticker: SLXNW · Form: 10-Q · Filed: May 13, 2025 · CIK: 2022416

Sentiment: neutral

Topics: 10-Q, reverse-split, financials, corporate-action

TL;DR

Silexion Therapeutics 10-Q filed. Post reverse split. G&A costs include advisors, leases.

AI Summary

Silexion Therapeutics Corp. filed a 10-Q for the period ending March 31, 2025. The company, formerly known as Biomotion Sciences, reported financial results after a 1-for-9 reverse share split effected on November 29, 2024. Other segment expenses include general and administrative costs such as advisor payments and office leases.

Why It Matters

This filing provides investors with an update on Silexion Therapeutics' financial performance and operational expenses following a significant corporate action, the reverse stock split.

Risk Assessment

Risk Level: medium — The company underwent a reverse stock split, which can sometimes indicate financial distress or an attempt to meet exchange listing requirements.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Silexion Therapeutics Corp?

Silexion Therapeutics Corp. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].

When did Silexion Therapeutics Corp. change its name?

The company changed its name from Biomotion Sciences to Silexion Therapeutics Corp. on May 6, 2024.

What period does this 10-Q filing cover?

This 10-Q filing covers the period ending March 31, 2025.

What is the significance of the reverse share split mentioned?

A 1-for-9 reverse share split was effected on November 29, 2024, and all share and per share amounts for the three months ended March 31, 2024, have been retroactively adjusted to reflect this split.

What types of expenses are included in 'Other segment expenses'?

Other segment expenses include general and administrative-related expenses such as payments to advisors and consultants, office lease expenses and maintenance, HR, and legal expenses.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Silexion Therapeutics Corp (SLXNW).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing